TIF News (IT)

Juggling Between The Cost And Value of New Therapies: Does Science Still Serve Patient Needs?

Juggling Between The Cost And Value of New Therapies: Does Science Still Serve Patient Needs?

In the aftermath of the withdrawal of Zynteglo, the first gene therapy for patients with β-thalassaemia, from Europe, TIF´s Executive Director, Dr Androulla Eleftheriou, reflects on the viability of the…
Coming Up This Thursday: Discussion On Access To Innovative Therapies – The Reblozyl Case

Coming Up This Thursday: Discussion On Access To Innovative Therapies – The Reblozyl Case

After receiving numerous questions from patients regarding the innovative treatment for β-thalassaemia Reblozyl (luspatercept), approved for use in the US, Europe, and Canada, TIF proceeds to organise an interactive, online…
TIF Takes Active Part In The 71st Session of the WHO Regional Committee for Europe

TIF Takes Active Part In The 71st Session of the WHO Regional Committee for Europe

TIF has participated in the 71st session of the WHO Regional Committee for Europe between 13–15 September 2021, which gathered six hundred high-level delegates, including over 30 Health Ministers from…
TIF Issues Charter of Priorities (CoP) For The Global PKD Patient Community

TIF Issues Charter of Priorities (CoP) For The Global PKD Patient Community

In the context of its educational and advocacy efforts within the field of other rare anaemias, beyond thalassaemia and sickle cell disease (SCD), and aiming, in particular, at the support…
TIF Presents The Federation’s Annual Report For 2020

TIF Presents The Federation’s Annual Report For 2020

“Our commitment to unite the patient voice and to advocate at the highest possible levels for equal access to all treatment options remains our number one priority.“ TIF President –…
TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education

TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education

Read. Learn. Empower. The Thalassaemia International Federation´s internationally acclaimed Educational Programme is a fundamental component of TIF´s work and is specifically designed for and addressed to the ever-growing learning needs…
Hemoglobin Disorders In Europe: A Systematic Effort Of Identifying And Addressing Unmet Needs And Challenges By TIF

Hemoglobin Disorders In Europe: A Systematic Effort Of Identifying And Addressing Unmet Needs And Challenges By TIF

The recent population movement has led to a steady increase of carriers and patients with haemoglobin disorders, namely thalassaemia and sickle cell disease, in all countries of the European Union.…
Back to top button